myasthenia%20gravis
MYASTHENIA GRAVIS
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.

Myasthenia%20gravis Signs and Symptoms

Definition

  • Myasthenia gravis is an uncommon neurological disorder caused by autoantibodies against the acetylcholine receptor, against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab), or occasionally to the low-density lipoprotein receptor-related protein 4 (LPR4)
    • The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission & eventually muscle weakness

Signs and Symptoms

  • Fatigability & weakness of voluntary muscles
    • Weakness tends to increase during repeated use
    • May improve with rest or sleep
  • Diplopia & ptosis
    • Common initial complaints
    • Generally asymmetrical
    • Cogan’s lid twitch or excessive lid elevation
  • Facial weakness which results in snarl-like expression when smiling
  • Nasal or slurred speech
  • Difficulty in swallowing
  • If generalized, there will be weakness in the limb muscles
    • Often asymmetric & proximal
  • Deep tendon reflexes & sensation are preserved
  • If severe, there will be shortness of breath

Clinical Features

  • Acetylcholine Receptor Myasthenia Gravis
    • Muscle weakness predominant in the limb than bulbar, neck extensor than neck flexor, prominent ptosis & external ocular muscle weakness
    • Wasting of proximal limb & ocular muscles in long-standing disease (myasthenic myopathy)
    • Thymus pathology: 65% hyperplasia, 15% thymoma
    • Risk of recurrent crisis is low
  • Muscle-Specific Tyrosine Kinase Myasthenia Gravis
    • Muscle weakness predominant in the bulbar than the limb, neck flexor than neck extensor, mild ptosis & external ocular muscle weakness
    • Early wasting of facial & tongue muscles
    • Thymus pathology: 10% hyperplasia
    • High-risk of recurrent crisis
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Jun 2020
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Roshini Claire Anthony, 19 Oct 2020

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.